body > *:not(noscript) { display: none !important; } noscript { display: block !important; } .no-js-warning { display: flex !important; min-height: 100vh; align-items: center; justify-content: center; padding: 20px; background: #f8f9fa; text-align: center; } .no-js-card { max-width: 500px; padding: 30px; border-radius: 12px; background: white; box-shadow: 0 10px 30px rgba(0,0,0,0.08); font-family: Arial, sans-serif; } .no-js-card h1 { margin-bottom: 10px; }

JavaScript Required

JavaScript is required for this website to work correctly and provide a smooth user experience. Please enable JavaScript in your browser, then refresh the page.

Back to PharmaIndex

DOLUTEGRAVIR, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

DOLUTEGRAVIR; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

Train on this drug

Drug details

API

DOLUTEGRAVIR; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

Drug classification

Dosage form

TABLET; ORAL

API strength per dosage

50MG/300MG/300MG

Dose

Mechanism of action

Indications

Side effects

Pregnancy category

Precautions

Contraindications

Interaction checker

Check interactions

Ask about possible interactions, counseling points, and safety considerations for this medicine.

Drug interaction assistant

Ask about DOLUTEGRAVIR, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE with another medicine, food, condition, or counseling concern.

PharmaProLearn

Excel Beyond Limits